Hypofractionated radiotherapy induces miR-34a expression and enhances apoptosis in human nasopharyngeal carcinoma cells

Long,Zhixiong; Wang,Bin; Tao,Dan; Huang,Ying; Tao,Zezhang

doi:10.3892/ijmm.2014.1937

Hypofractionated radiotherapy induces miR-34a expression and enhances apoptosis in human nasopharyngeal carcinoma cells

Authors:
- Zhixiong Long
- Bin Wang
- Dan Tao
- Ying Huang
- Zezhang Tao
View Affiliations

Affiliations: Department of Otolaryngology-Head and Neck Surgery, Renmin Hospital of Wuhan University, Wuhan, Hubei 430060, P.R. China, Department of Otolaryngology (ENT), The Fifth Hospital of Wuhan, Wuhan, Hubei 430051, P.R. China, Department of Oncology, The Fifth Hospital of Wuhan, Wuhan, Hubei 430051, P.R. China
Published online on: September 17, 2014 https://doi.org/10.3892/ijmm.2014.1937
Pages: 1388-1394

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Nasopharyngeal carcinoma (NPC) is a relatively radiosensitive disease. However, the therapeutic effects of radiotherapy are not always satisfactory due to radioresistance. The hypofractionated schema is currently widely used in clinical practice. In the present study, we investigated the effects of hypofractionated radiotherapy on NPC cells and explored the mechanisms involved. In addition, we aimed to determine the role of miR-34a in the effects of hypofractionated radiotherapy and whether these effects occur in a p53-dependent manner. For this purpose, we used CNE1 and CNE2 NPC cells which were subjected to hyperfractionated and hypofractionated radiotherapy. The viability of the cells was measured by MTT assay and acridine orange (AO) and ethidium bromide (EB) staining was used to observe morphological changes. In addition, Annexin V-propidium iodide (PI) staining and flow cytometry were used to determine the number of apoptotic cells and mRNA and protein expression was measured by qPCR and western blot analysis, respectively. The results revealed that hypofractionated radiotherapy enhanced apoptosis and increased the expression of miR-34a and p53 in the NPC cells. In addition, it stimulated p53 promoter activity and downregulated the protein expression of c-Myc in the human NPC cells. Furthermore, the knockdown of miR-34a suppressed the growth inhibitory effects induced by hypofractionated radiotherapy. Thus, our results suggest that the enhanced apoptosis of NPC cells may be associated with the miR-34a-mediated suppression of c-Myc in a p53-dependent manner.

View Figures

View References

1	Orecchia R, Redda MG, Ragona R, et al: Results of hypofractionated stereotactic re-irradiation on 13 locally recurrent nasopharyngeal carcinomas. Radiother Oncol. 53:23–28. 1999. View Article : Google Scholar : PubMed/NCBI
2	Pan Y, Wang M, Bu X, et al: Curcumin analogue T83 exhibits potent antitumor activity and induces radiosensitivity through inactivation of Jab1 in nasopharyngeal carcinoma. BMC Cancer. 13:3232013. View Article : Google Scholar
3	Wu JS, Brasher PM, El-Gayed A, et al: Phase II study of hypofractionated image-guided radiotherapy for localized prostate cancer: outcomes of 55 Gy in 16 fractions at 3.4 Gy per fraction. Radiother Oncol. 103:210–216. 2012. View Article : Google Scholar : PubMed/NCBI
4	Schneider U, Besserer J and Mack A: Hypofractionated radiotherapy has the potential for second cancer reduction. Theor Biol Med Model. 7:42010. View Article : Google Scholar : PubMed/NCBI
5	Bakst RL, Lee N, Pfister DG, et al: Hypofractionated dose-painting intensity modulated radiation therapy with chemotherapy for nasopharyngeal carcinoma: a prospective trial. Int J Radiat Oncol Biol Phys. 80:148–153. 2011. View Article : Google Scholar : PubMed/NCBI
6	Friedman JM, Jones PA and Liang G: The tumor suppressor microRNA-101 becomes an epigenetic player by targeting the polycomb group protein EZH2 in cancer. Cell Cycle. 8:2313–2314. 2009. View Article : Google Scholar : PubMed/NCBI
7	Jiang P, Rao EY, Meng N, Zhao Y and Wang JJ: MicroRNA-17–92 significantly enhances radioresistance in human mantle cell lymphoma cells. Radiat Oncol. 5:1002010.
8	Welch C, Chen Y and Stallings RL: MicroRNA-34a functions as a potential tumor suppressor by inducing apoptosis in neuroblastoma cells. Oncogene. 26:5017–5022. 2007. View Article : Google Scholar : PubMed/NCBI
9	Liu X, Luo HN, Tian WD, et al: Diagnostic and prognostic value of plasma microRNA deregulation in nasopharyngeal carcinoma. Cancer Biol Ther. 14:1133–1142. 2013. View Article : Google Scholar : PubMed/NCBI
10	Chen HC, Chen GH, Chen YH, et al: MicroRNA deregulation and pathway alterations in nasopharyngeal carcinoma. Br J Cancer. 100:1002–1011. 2009. View Article : Google Scholar : PubMed/NCBI
11	Ghawanmeh T, Thunberg U, Castro J, Murray F and Laytragoon-Lewin N: miR-34a expression, cell cycle arrest and cell death of malignant mesothelioma cells upon treatment with radiation, docetaxel or combination treatment. Oncology. 81:330–335. 2011. View Article : Google Scholar : PubMed/NCBI
12	Liu C, Zhou C, Gao F, et al: MiR-34a in age and tissue related radio-sensitivity and serum miR-34a as a novel indicator of radiation injury. Int J Biol Sci. 7:221–233. 2011. View Article : Google Scholar : PubMed/NCBI
13	Kang J, Kim E, Kim W, et al: Rhamnetin and cirsiliol induce radiosensitization and inhibition of epithelial-mesenchymal transition (EMT) by miR-34a-mediated suppression of Notch-1 expression in non-small cell lung cancer cell lines. J Biol Chem. 288:27343–27357. 2013. View Article : Google Scholar : PubMed/NCBI
14	John-Aryankalayil M, Palayoor ST, Makinde AY, et al: Fractionated radiation alters oncomir and tumor suppressor miRNAs in human prostate cancer cells. Radiat Res. 178:105–117. 2012. View Article : Google Scholar : PubMed/NCBI
15	Boysen J, Sinha S, Price-Troska T, et al: The tumor suppressor axis p53/miR-34a regulates Axl expression in B-cell chronic lymphocytic leukemia: implications for therapy in p53-defective CLL patients. Leukemia. 28:451–455. 2013. View Article : Google Scholar : PubMed/NCBI
16	Su W, Hopkins S, Nesser NK, et al: The p53 transcription factor modulates microglia behavior through microRNA-dependent regulation of c-Maf. J Immunol. 92:358–366. 2013.PubMed/NCBI
17	Stankevicins L, Almeida da Silva AP, Ventura Dos Passos F, et al: MiR-34a is up-regulated in response to low dose, low energy X-ray induced DNA damage in breast cells. Radiat Oncol. 8:2312013. View Article : Google Scholar : PubMed/NCBI
18	Qu Y, Zhao S, Hong J and Tang S: Radiosensitive gene therapy through imRNA expression for silencing manganese superoxide dismutase. J Cancer Res Clin Oncol. 136:953–959. 2010. View Article : Google Scholar : PubMed/NCBI
19	Feng XP, Yi H, Li MY, et al: Identification of biomarkers for predicting nasopharyngeal carcinoma response to radiotherapy by proteomics. Cancer Res. 70:3450–3462. 2010. View Article : Google Scholar : PubMed/NCBI
20	Bourgier C, Lemanski C, Riou O, Charissoux M, Fenoglietto P and Azria D: Hypofractionated radiotherapy, a standard in breast cancer? Cancer Radiother. 17:705–707. 2013.(In French).
21	Tortorelli G, Di Murro L, Barbarino R, et al: Standard or hypofractionated radiotherapy in the postoperative treatment of breast cancer: a retrospective analysis of acute skin toxicity and dose inhomogeneities. BMC Cancer. 13:2302013. View Article : Google Scholar : PubMed/NCBI
22	Ishiyama H, Satoh T, Kitano M, et al: High-dose-rate brachytherapy and hypofractionated external beam radiotherapy combined with long-term hormonal therapy for high-risk and very high-risk prostate cancer: outcomes after 5-year follow-up. J Radiat Res. 55:509–517. 2013.PubMed/NCBI
23	Huang BS, Tsang NM, Lin SM, et al: High-dose hypofractionated X-ray radiotherapy for hepatocellular carcinoma: Tumor responses and toxicities. Oncol Lett. 6:1514–1520. 2013.PubMed/NCBI
24	Bush DA, Cheek G, Zaheer S, et al: High-dose hypofractionated proton beam radiation therapy is safe and effective for central and peripheral early-stage non-small cell lung cancer: results of a 12-year experience at Loma Linda University Medical Center. Int J Radiat Oncol Biol Phys. 86:964–968. 2013.PubMed/NCBI
25	Mouw KW and Harris JR: Hypofractionation in the era of modulated radiotherapy (RT). Breast. 22(Suppl 2): S129–S136. 2013. View Article : Google Scholar : PubMed/NCBI
26	Fowler JF: The radiobiology of prostate cancer including new aspects of fractionated radiotherapy. Acta Oncol. 44:265–276. 2005. View Article : Google Scholar : PubMed/NCBI
27	Debenham BJ, Hu KS and Harrison LB: Present status and future directions of intraoperative radiotherapy. Lancet Oncol. 14:e457–e464. 2013. View Article : Google Scholar : PubMed/NCBI
28	Mendrysa SM, Ghassemifar S and Malek R: p53 in the CNS: perspectives on development, stem cells, and cancer. Genes Cancer. 2:431–442. 2011. View Article : Google Scholar : PubMed/NCBI
29	Muaddi H, Chowdhury S, Vellanki R, Zamiara P and Koritzinsky M: Contributions of AMPK and p53 dependent signaling to radiation response in the presence of metformin. Radiother Oncol. 108:446–450. 2013. View Article : Google Scholar : PubMed/NCBI
30	Huerta S, Gao X, Dineen S, Kapur P, Saha D and Meyer J: Role of p53, Bax, p21, and DNA-PKcs in radiation sensitivity of HCT-116 cells and xenografts. Surgery. 154:143–151. 2013. View Article : Google Scholar : PubMed/NCBI
31	Gilbert DC, Williams A, Allan K, et al: p16^INK4A, p53, EGFR expression and KRAS mutation status in squamous cell cancers of the anus: correlation with outcomes following chemo-radiotherapy. Radiother Oncol. 109:146–151. 2013.
32	Guo Y, Parry JJ, Laforest R, Rogers BE and Anderson CJ: The role of p53 in combination radioimmunotherapy with 64Cu-DOTA-cetuximab and cisplatin in a mouse model of colorectal cancer. J Nucl Med. 54:1621–1629. 2013. View Article : Google Scholar : PubMed/NCBI
33	Xie X, Jin H, Hu J, et al: Association between single nucleotide polymorphisms in the p53 pathway and response to radiotherapy in patients with nasopharyngeal carcinoma. Oncol Rep. 31:223–231. 2014.PubMed/NCBI
34	Yang CF, Peng LX, Huang TJ, et al: Cancer stem-like cell characteristics induced by EB virus-encoded LMP1 contribute to radioresistance in nasopharyngeal carcinoma by suppressing the p53-mediated apoptosis pathway. Cancer Lett. 344:260–271. 2013. View Article : Google Scholar : PubMed/NCBI
35	Siemens H, Jackstadt R, Kaller M and Hermeking H: Repression of c-Kit by p53 is mediated by miR-34 and is associated with reduced chemoresistance, migration and stemness. Oncotarget. 4:1399–1415. 2013.PubMed/NCBI
36	Yoshizaki T, Ito M, Murono S, Wakisaka N, Kondo S and Endo K: Current understanding and management of nasopharyngeal carcinoma. Auris Nasus Larynx. 39:137–144. 2012. View Article : Google Scholar
37	Hermeking H: The miR-34 family in cancer and apoptosis. Cell Death Differ. 17:193–199. 2010. View Article : Google Scholar : PubMed/NCBI
38	Jain M, Arvanitis C, Chu K, et al: Sustained loss of a neoplastic phenotype by brief inactivation of MYC. Science. 297:102–104. 2002. View Article : Google Scholar : PubMed/NCBI
39	Doherty JR, Yang C, Scott KE, et al: Blocking lactate export by inhibiting the Myc target MCT1 disables glycolysis and glutathione synthesis. Cancer Res. 74:908–920. 2013. View Article : Google Scholar : PubMed/NCBI
40	Yamamura S, Saini S, Majid S, et al: MicroRNA-34a suppresses malignant transformation by targeting c-Myc transcriptional complexes in human renal cell carcinoma. Carcinogenesis. 33:294–300. 2012. View Article : Google Scholar : PubMed/NCBI